Abstracts Archive - Page 1845 of 2607 - ACR Meeting Abstracts

Abstract Number: 2869 • 2015 ACR/ARHP Annual Meeting
Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis
Louis Bessette¹, Proton Rahman², Denis Choquette³, John Kelsall⁴, Maqbool Sheriff⁵, Emmanouil Rampakakis⁶, Eliofotisti Psaradellis⁷, Allen J Lehman⁸, Karina Maslova⁸, Francois Nantel^9,10, Brendan Osborne¹¹ and Cathy Tkaczyk¹¹, ¹Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: : Previous controlled clinical trials have shown that concurrent methotrexate (MTX) therapy may enhance the efficacy of anti-TNF agents. However, real-world data on the…
Abstract Number: 2870 • 2015 ACR/ARHP Annual Meeting
Predictors of Early Minimal Disease Activity in Psa Patients Treated with Anti-TNF in a Real-World Registry
Michel Zummer¹, Proton Rahman², Regan Arendse³, Michael Starr⁴, John Kelsall⁵, J Antonio Avina-Zubieta⁶, Philip Baer⁷, Dalton Sholter⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Karina Maslova¹³, Francois Nantel¹⁴, Allen J Lehman¹³ and Cathy Tkaczyk¹², ¹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology, McGill University, Montreal, QC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁷Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁸Rheumatology Associates, Edmonton, AB, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current analysis…
Abstract Number: 2871 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period
Denis Choquette¹, Proton Rahman², Maqbool Sheriff³, Wojciech Olszynski⁴, Emmanouil Rampakakis⁵, Eliofotisti Psaradellis⁶, Francois Nantel⁷, Brendan Osborne⁸, Allen J Lehman⁹, Karina Maslova⁹ and Cathy Tkaczyk⁸, ¹Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada, ⁶JSS Medical Research, Montreal, QC, Canada, ⁷19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ⁸Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Although the efficacy and tolerability of golimumab (GLM) in patients with ankylosing spondylitis (AS) has been demonstrated in several controlled clinical trials, it is…
Abstract Number: 2872 • 2015 ACR/ARHP Annual Meeting
Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
Mark C. Genovese¹, Philip J. Mease², Maria Greenwald³, Christopher T. Ritchlin⁴, Andre Beaulieu⁵, Atul A. Deodhar⁶, Richard Newmark⁷, JingYuan Feng⁸, Ngozi Erondu⁹ and Ajay Nirula¹⁰, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Desert Medical Advances, Palm Desert, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Faculty of Medicine, University of Laval, Quebec, QC, Canada, ⁶Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷Clinical Affairs, Amgen, Thousand Oaks, CA, ⁸Amgen Inc., Thousand Oaks, CA, ⁹Inflammation, Amgen, Inc., Thousand Oaks, CA, ¹⁰Amgen Inc, Thousand Oaks, CA
Background/Purpose: The interleukin-17 (IL-17) cytokine family plays a key role in the pathogenesis of psoriatic diseases of skin and joint. Brodalumab is a fully human…
Abstract Number: 2873 • 2015 ACR/ARHP Annual Meeting
Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA
Sofia Ramiro¹, Josef S. Smolen², Robert B.M. Landewé³, Désirée van der Heijde¹, Maxime Dougados⁴, Paul Emery⁵, Maarten de Wit⁶, Maurizio Cutolo⁷, Susan Oliver⁸ and Laure Gossec⁹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology Department, Cochin hospital, Paris-Descartes University, Paris, France, ⁵Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁶EULAR Social Leagues, Zurich, Switzerland, ⁷Division of Clinical Immunology, Dept Internal Medicine, University of Genova, Genova, Italy, ⁸Independent Nurse Consultant, North Devon, United Kingdom, ⁹Rheumatology, Pitié Salpetriere Hospital, Paris, France
Background/Purpose: As part of the update of the EULAR recommendations for the management of PsA, we performed a systematic literature review to assess the efficacy…
Abstract Number: 2874 • 2015 ACR/ARHP Annual Meeting
Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Leonardo Santo¹, Angelo Semeraro², Carmelo Zuccaro³, Maria Grazia Anelli⁴, Romano Bucci⁵, Antonio Marsico⁶, Laura Quarta⁷, Giorgio Carlino⁸, Francesco Paolo Cantatore⁹, Annamaria Gaudio¹⁰, Fabio Cacciapaglia¹¹, Oriana Casilli¹², Paola Chiara Francesca Falappone¹³ and Florenzo Iannone¹⁴, ¹DSS4 Barletta, ASL BT Andria - Rheumatology Service, Barletta, Italy, ²Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ³U.O.of Geriatrics, Outpatient clinic of Rheumatology, Brindisi, Italy, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵A.O.U., Rheumatology Hospital Unit, Foggia, Italy, ⁶Outpatient clinic of Rheumatology, Taranto,, Italy, ⁷Department of Rheumatology, "V.Fazzi" Hospital, San Cesario di Lecce, Italy, ⁸ASL LE - DSS Casarano and Gallipoli, Rheumatology Service, Gallipoli, Italy, ⁹Department of Rheumatology, University of Foggia,, Foggia, Italy, ¹⁰Department of Rheumatology, University of Foggia, Foggia, Italy, ¹¹Internal Medicine Unit and Outpatient clinic of Rheumatology, “N. Melli” Hospital, San Pietro Vernotico (BR), Italy, ¹²Department of Rheumatology, "Vito Fazzi" Hospital, San Cesario di Lecce, Italy, ¹³Internal Medicine Unit - Outpatient clinic of Rheumatology,, "S. Camillo de' Lellis" Hospital, Mesagne (BR), Italy, ¹⁴Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy
Background/Purpose: It has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis1. The objective…
Abstract Number: 2875 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Not Associated with an Increase in Neoplasias in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Fabiola Atzeni¹, Antonio Carletto², Marco Sebastiani³, Valentina Panetta⁴, Fausto Salaffi⁵, Florenzo Iannone⁶, Elisa Gremese⁷, Marcello Govoni⁸, Antonio Marchesoni⁹, Roberto Gorla¹⁰, Roberta Ramonda¹¹, Pier Carlo Sarzi-Puttini¹², Gianfranco Ferraccioli⁷, Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy, ³SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ⁴L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁵Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁶Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁷Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ⁸Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ⁹Rheumatology Unit, Orthopedic Institute G. Pini, Milano, Italy, ¹⁰Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ¹¹Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ¹²Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: The use of TNF inhibitors (TNFIs) has led to efficient control of the signs and symptoms of SpA and rheumatoid arthritis (RA), and significantly…
Abstract Number: 2876 • 2015 ACR/ARHP Annual Meeting
Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Maxime Dougados¹, Gina Bergman², Walter Maksymowych³, Sean P. Curtis², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Paris-Descartes University, Paris, France, ²Merck & Co., Inc., Kenilworth, NJ, ³University of Alberta, Edmonton, AB, Canada, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Subgroup analyses can be used to investigate the size and direction of treatment effects across a range of demographic and disease characteristics. The purpose…
Abstract Number: 2877 • 2015 ACR/ARHP Annual Meeting
What Is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
John Kelsall¹, Denis Choquette², Proton Rahman³, Regan Arendse⁴, Michelle Teo⁵, Isabelle Fortin⁶, J Antonio Avina-Zubieta⁷, Emmanouil Rampakakis^8,9, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹, Francois Nantel¹² and Allen J Lehman¹⁰, ¹Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ²Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ³Medicine, Memorial University, St John's, NF, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁶Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁷Arthritis Research Canada, Richmond, BC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Enthesitis is characterized by inflammation at the insertion of ligaments, tendons, joint capsule, or fascia to bone, and represents a well-known characteristic feature of…
Abstract Number: 2878 • 2015 ACR/ARHP Annual Meeting
Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents
Sara Monti, Veronica Codullo, Vittorio Grosso, Silvia Breda, Carlomaurizio Montecucco and Roberto Caporali, Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy
Background/Purpose: The treat to target strategy (T2T), aiming at inactive disease (ID), has become the recommended approach also in the field of axial-SpA (axSpA) (1). …
Abstract Number: 2879 • 2015 ACR/ARHP Annual Meeting
What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
Regan Arendse¹, Proton Rahman², Denis Choquette³, J Antonio Avina-Zubieta⁴, Michel Zummer⁵, Milton F. Baker⁶, Jacqueline Stewart⁷, Isabelle Fortin⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Cathy Tkaczyk¹², Karina Maslova¹³, Francois Nantel¹⁴ and Allen J Lehman¹³, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ⁶VIHA, Victoria, BC, Canada, ⁷Penticton Regional Hospital, Penticton, BC, Canada, ⁸Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Dactylitis is one of the most commonly reported features in spondyloarthritis. It has been hypothesized that dactylitis is a functional enthesitis at the proximal…
Abstract Number: 2880 • 2015 ACR/ARHP Annual Meeting
Real-World Impact of Anti-TNF Medication Use on Patient Reported Outcomes in a Prospective Cohort of Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Annelies Boonen², Helena Marzo-Ortega³, Marina N. Magrey⁴, Manish Mittal⁵, Michael Halpern⁶, Jeanette Renaud⁶, Yanjun Bao⁵ and Avani D. Joshi⁵, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Maastricht University Medical Center, Maastricht, Netherlands, ³LMBRU, Chapel Allerton Hospital, and University of Leeds, Leeds, United Kingdom, ⁴Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ⁵AbbVie Inc., North Chicago, IL, ⁶RTI International, Washington, DC
Background/Purpose: Clinical trial results have demonstrated benefits of anti-TNF therapy in improving clinical outcomes, including overall health-related quality of life (HRQoL) in patients with ankylosing…
Abstract Number: 2881 • 2015 ACR/ARHP Annual Meeting
Infliximab in Spondyloarthritis Patients: Utility of Drug Level Monitoring
Claudia Deaconu¹, Diana Mazilu², Laura Grosanu², Ioana Saulescu², Andreea Borangiu², Cecilia Gainaru³, Cosmin Constantinescu², Violeta Bojinca², Violeta Vlad¹, Andra Balanescu², Denisa Predeteanu², Ruxandra Ionescu² and Daniela Opris², ¹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ³"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Spondyloarthritides, a heterogeneous group of chronic, inflammatory disorders with overlapping organ and joint targeting, share the same therapeutic approach in regard to biological therapy.…
Abstract Number: 2882 • 2015 ACR/ARHP Annual Meeting
Baseline Extent of Damage at the Spine Predicts Radiographic Progression in Korean Patients Using Golimumab for Ankylosing Spondylitis
Jeong Seok Lee¹, Dae Young Yu², Stephen Xu³ and Eun Young Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University Hospital, Seoul, South Korea, ²Medical Affairs, Janssen Korea, Seoul, South Korea, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic rheumatic disease associated with radiographic damage of the spine. Golimumab had consistent efficacy in controlling disease activity through…
Abstract Number: 2883 • 2015 ACR/ARHP Annual Meeting
Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Laure Gossec¹, Tore K. Kvien², Philip G. Conaghan³, Mikkel Østergaard⁴, Juan D. Cañete⁵, C. Gaillez⁶, Shephard Mpofu⁶, Bintu Sherif⁷ and Steffen Jugl⁸, ¹Rheumatology Department, Paris 06 University,Hôpital Pitié Salpêtrière, Paris, France, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Durham, NC, ⁸BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Fatigue is highly important to patients (pts) with psoriatic arthritis (PsA). Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved the signs and symptoms of active…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].